Back to Search
Start Over
A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
- Source :
- Scientific Reports
- Publication Year :
- 2013
- Publisher :
- Springer Science and Business Media LLC, 2013.
-
Abstract
- A preclinical trial identified 4 of 20 (20%) gastric cancer (GC) patient-derived xenografts responded to cetuximab. Genome-wide profiling and additional investigations revealed that high EGFR mRNA expression and immunohistochemistry score (3+) are associated with tumor growth inhibition. Furthermore, EGFR amplification were observed in 2/4 (50%) responders with average copy number 5.8 and >15 respectively. Our data suggest that a GC subtype with EGFR amplification and overexpression benefit from cetuximab treatment.
- Subjects :
- Cetuximab
Gene Expression
Antineoplastic Agents
Antibodies, Monoclonal, Humanized
Article
Mice
Stomach Neoplasms
Gene duplication
Gene expression
medicine
Animals
Humans
Regulation of gene expression
Multidisciplinary
biology
Gene Expression Profiling
Gene Amplification
Xenograft Model Antitumor Assays
Molecular biology
digestive system diseases
Tumor Burden
ErbB Receptors
Gene Expression Regulation, Neoplastic
Gene expression profiling
Disease Models, Animal
Treatment Outcome
Mutation
Monoclonal
biology.protein
Cancer research
Immunohistochemistry
Female
Antibody
medicine.drug
Subjects
Details
- ISSN :
- 20452322
- Volume :
- 3
- Database :
- OpenAIRE
- Journal :
- Scientific Reports
- Accession number :
- edsair.doi.dedup.....be7a6a0cf02af6d5fdcc5830298d1316
- Full Text :
- https://doi.org/10.1038/srep02992